DHODH Drives Sunitinib Resistance Via a Non‐Enzymatic Mechanism by Inhibiting TRIM28 Ubiquitination and Consequent VEGFA Activation in RCC
Advanced Science · 2026
DOI: 10.1002/advs.76266 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2026. Verfasst von Shijie Qian und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, First Affiliated Hospital of Nanjing Medical University, Nanjing, China. Hauptthemen laut MEDLINE: Sunitinib, Carcinoma, Renal Cell, Drug Resistance, Neoplasm, Vascular Endothelial Growth Factor A. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Jiangsu Provincial Medical Key Discipline (Laboratory), Young Scholars Fostering Fund of the First Affiliated Hospital of Nanjing Medical University, National Natural Science Foundation of China.
Abstract (Originalsprache)
Sunitinib, a tyrosine kinase inhibitor, exerts its crucial therapeutic effect in renal cell carcinoma (RCC) primarily by inhibiting tumor angiogenesis and cellular proliferation. However, despite its initial efficacy, therapeutic resistance invariably develops in many RCC patients, underscoring the urgent need for novel strategies to overcome this limitation. We constructed patient‐derived xenograft (PDX) models using surgically resected RCC tissues and subsequently established stable sunitinib‐resistant and sunitinib‐sensitive PDX models. Proteomic profiling was performed to identify key regulators involved in sunitinib resistance. Mechanistic studies were conducted to investigate the molecular interactions among DHODH, TRIM28, and VEGFA. The therapeutic potential of lisaftoclax was evaluated in combination with sunitinib. Proteomic profiling identified DHODH as a key regulator in the development of sunitinib resistance in RCC. Mechanistically, DHODH competes with the E3 ligase TRIM37 for binding to TRIM28, thereby stabilizing TRIM28 by inhibiting its ubiquitination. TRIM28 subsequently activates VEGFA transcription, which promotes sunitinib resistance in RCC. Lisaftoclax, a small‐molecule inhibitor that disrupts the DHODH‐TRIM28 interaction, potentiates sunitinib efficacy and exerts a synergistic therapeutic effect. Collectively, our findings identify DHODH as a critical therapeutic target for overcoming sunitinib resistance in RCC and provide a novel strategy for the treatment of RCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
ORCID-Profile: Shijie Qian, Shihang Pu, Zengjun Wang, Jiajun Xing, Aiming Xu
Förderung
- Jiangsu Provincial Medical Key Discipline (Laboratory)
- Young Scholars Fostering Fund of the First Affiliated Hospital of Nanjing Medical University
- National Natural Science Foundation of China
- Natural Science Foundation of Jiangsu Province
- China Postdoctoral Science Foundation
Zitieren
APA
Qian, S., Pu, S., Xu, Z., Ding, Y., Jin, L., Li, B., Li, Q., Xi, X., Wang, Z., Xing, J., & Xu, A. (2026). DHODH Drives Sunitinib Resistance Via a Non‐Enzymatic Mechanism by Inhibiting TRIM28 Ubiquitination and Consequent VEGFA Activation in RCC. Advanced Science. https://doi.org/10.1002/advs.76266
Vancouver
Qian S, Pu S, Xu Z, Ding Y, Jin L, Li B, et al. DHODH Drives Sunitinib Resistance Via a Non‐Enzymatic Mechanism by Inhibiting TRIM28 Ubiquitination and Consequent VEGFA Activation in RCC. Advanced Science. 2026. doi:10.1002/advs.76266
BibTeX
@article{Qian2026,
author = {Qian, Shijie and Pu, Shihang and Xu, Zhipeng and Ding, Yiheng and Jin, Ling and Li, Baochao and Li, Qi and Xi, Xiaohai and Wang, Zengjun and Xing, Jiajun and Xu, Aiming},
title = {DHODH Drives Sunitinib Resistance Via a Non‐Enzymatic Mechanism by Inhibiting TRIM28 Ubiquitination and Consequent VEGFA Activation in RCC},
journal = {Advanced Science},
year = {2026},
doi = {10.1002/advs.76266}
}
EUVIMED